Ser32
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser32  -  IkB-alpha (human)

Site Information
LLDDRHDsGLDsMkD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448203

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 106 ) , [32P] bio-synthetic labeling ( 58 , 64 , 101 , 106 ) , electrophoretic mobility shift ( 65 , 79 , 101 ) , immunoassay ( 28 ) , immunoprecipitation ( 1 , 2 , 3 , 6 , 26 ) , mass spectrometry ( 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 27 , 32 , 37 , 38 , 39 , 40 , 41 ) , mutation of modification site ( 1 , 2 , 4 , 42 , 52 , 55 , 58 , 64 , 65 , 67 , 69 , 74 , 75 , 76 , 80 , 82 , 88 , 89 , 92 , 93 , 101 , 104 , 105 , 106 ) , peptide sequencing ( 31 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 8 , 21 , 23 , 24 , 26 , 28 , 29 , 34 , 35 , 42 , 43 , 44 , 45 , 46 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 77 , 78 , 79 , 80 , 81 , 83 , 84 , 85 , 90 , 91 ) , phosphopeptide mapping ( 101 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 8 , 21 , 23 , 24 , 26 , 29 , 31 , 34 , 35 , 42 , 43 , 44 , 45 , 46 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 62 , 64 , 66 , 67 , 69 , 71 , 73 , 78 , 80 , 89 , 91 , 104 , 105 )
Disease tissue studied:
bone cancer ( 21 ) , brain cancer ( 23 , 29 ) , glioblastoma ( 23 , 29 ) , glioblastoma multiforme ( 23 ) , glioma ( 23 , 29 ) , HER2 positive breast cancer ( 7 ) , luminal B breast cancer ( 7 ) , cervical cancer ( 34 ) , cervical squamous cell carcinoma ( 34 ) , colorectal cancer ( 5 , 6 , 21 , 52 , 67 ) , colorectal carcinoma ( 5 , 6 , 21 , 52 , 67 ) , endometrial cancer ( 55 ) , endometrial adenocarcinoma ( 55 ) , gastric cancer ( 2 , 27 , 41 ) , gastric carcinoma ( 2 , 27 , 41 ) , leukemia ( 5 , 62 , 66 ) , acute myelogenous leukemia ( 62 , 66 ) , T cell leukemia ( 5 ) , liver cancer ( 31 ) , lung cancer ( 3 , 32 , 35 , 37 , 38 , 39 , 40 , 44 , 45 , 54 , 63 ) , non-small cell lung cancer ( 3 , 32 , 37 , 38 , 39 , 40 , 45 ) , non-small cell lung adenocarcinoma ( 32 ) , non-small cell squamous cell lung carcinoma ( 32 ) , lymphoma ( 88 , 90 ) , T cell lymphoma ( 88 ) , ovarian cancer ( 80 )
Relevant cell line - cell type - tissue:
'epithelial, lung' ( 44 ) , 16MB9A (breast cell) ( 77 ) , 267B1 (epithelial) ( 75 ) , 293 (epithelial) [IRAK1 (human)] ( 56 ) , 293 (epithelial) ( 42 , 56 , 67 , 74 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 101 ) , 3T3 (fibroblast) ( 89 ) , A549 (pulmonary) ( 35 , 44 , 45 , 54 , 63 ) , AGS (gastric) ( 2 ) , BAEC (endothelial) ( 46 , 71 ) , blood ( 65 ) , breast ( 7 ) , Caco-2 (intestinal) ( 6 , 52 ) , CCRF-CEM (T lymphocyte) ( 53 ) , cervix ( 68 ) , DU 145 (prostate cell) ( 81 ) , EL-4 (T lymphocyte) [IkB-alpha (human)] ( 106 ) , EL-4 (T lymphocyte) ( 88 ) , endometrium ( 55 ) , endothelial ( 46 ) , fibroblast-skin ( 65 ) , HCT116 (intestinal) ( 21 ) , HEK293T (epithelial) ( 1 , 3 , 65 , 94 ) , HeLa (cervical) ( 21 , 24 , 26 , 42 , 69 , 83 , 91 , 92 , 94 , 101 , 104 ) , HepG2 (hepatic) ( 31 ) , HT-29 (intestinal) ( 5 , 67 , 84 ) , hTERT-HME1 ( 8 ) , HUVEC (endothelial) ( 43 , 60 ) , Ishikawa (endometrial) ( 55 ) , J774 (macrophage) ( 78 ) , JB (epithelial) ( 57 ) , JPM50.6 (T lymphocyte) ( 51 ) , Jurkat (T lymphocyte) ( 5 , 19 , 49 , 51 , 53 , 64 , 92 , 105 ) , KB (squamous) ( 34 ) , KBM-5 (myeloid) ( 70 ) , LN229 (glial) ( 23 , 58 ) , LNCaP (prostate cell) ( 81 ) , lung ( 37 , 38 , 39 , 40 , 54 ) , M-07e (myeloid) ( 72 ) , M059J (glial) ( 29 ) , M059K (glial) ( 29 ) , MCF-7 (breast cell) ( 77 ) , MEF (fibroblast) ( 46 ) , MEF (fibroblast) [PKR (mouse), homozygous knockout] ( 91 ) , microglia ( 76 ) , MKN-45 (gastric) ( 27 , 41 ) , monocyte ( 73 , 79 ) , NCI-H1299 (pulmonary) ( 3 , 45 ) , NCI-H1703 (squamous) ( 9 , 32 ) , NCM460 (epithelial) ( 50 ) , OV2008 (ovarian) ( 80 ) , ovarian ( 26 ) , PC CL 3 (thyroid cell) [TR-beta1 (human), transfection] ( 4 ) , PC3 (prostate cell) ( 59 , 81 ) , RAW 264 (macrophage) ( 66 ) , SH-SY5Y (neural crest) ( 58 , 85 ) , T lymphocyte-blood ( 65 ) , T84 (intestinal) ( 52 ) , T98G (glial) ( 23 ) , THP1 (myeloid) ( 62 , 66 ) , U-937 (myeloid) ( 90 , 93 ) , U2OS (bone cell) ( 21 ) , U737 (glial) ( 58 )

Upstream Regulation
Regulatory protein:
AlphaK3 (human) ( 2 ) , CARD11 (human) ( 49 ) , CYBB (human) ( 35 ) , DDX58 (human) ( 35 ) , EGFR (human) ( 8 ) , IkB-alpha (human) ( 61 ) , IKKB (human) ( 55 , 61 ) , IKKG (human) ( 31 ) , LMP1 (herpesvirus) ( 56 ) , MAVS (human) ( 35 ) , MDA5 (human) ( 35 ) , PKR (mouse) ( 91 ) , PLCE1 (human) ( 6 ) , PLK1 (human) ( 42 ) , PRKD2 (human) ( 50 ) , SGK1 (human) ( 61 ) , SHIP (human) ( 53 ) , TIFA (human) ( 2 ) , TR-beta1 (human) ( 4 ) , TRAF2 (human) ( 35 ) , TRAF3 (human) ( 35 ) , TRAF6 (human) ( 35 )
Putative in vivo kinases:
ERK7 (human) ( 3 ) , IKKB (human) ( 92 ) , IKKE (human) ( 92 ) , RSK2 (human) ( 33 )
Kinases, in vitro:
AurC (human) ( 1 ) , CK2A1 (human) ( 93 , 95 ) , ERK7 (human) ( 3 ) , IKKA (human) ( 80 , 87 , 95 , 98 , 99 ) , IKKB (human) ( 48 , 87 , 98 ) , Nik (human) ( 96 ) , p90RSK (human) ( 95 ) , RSK2 (human) ( 33 ) , SGK1 (human) ( 61 )
Treatments:
15d-PGJ2 ( 43 ) , actinomycin_D ( 51 ) , anti-CD28 ( 64 ) , anti-CD3 ( 64 ) , anti-CD3/CD28 ( 51 ) , anti-LT(beta)R ( 67 ) , bacterial infection ( 52 ) , betulinic_acid ( 58 ) , bisindolylmaleimide ( 64 ) , bortezomib ( 55 ) , bradykinin ( 63 ) , cAMP_analog ( 74 ) , carrageenan ( 22 ) , ciclosporin ( 23 ) , cycloheximide ( 51 ) , deferoxamine ( 46 ) , DPI ( 44 ) , EGCG ( 79 ) , EGF ( 47 ) , estradiol ( 62 ) , FeTPPS ( 79 ) , GBS ( 73 ) , gomisin_A ( 24 ) , gomisin_N ( 24 ) , H2O2 ( 53 ) , heregulin ( 77 ) , hypoxia ( 30 ) , hypoxia/reoxygenation ( 69 ) , IGF-1 ( 61 ) , IL-1a ( 83 , 101 ) , IL-1b ( 34 , 52 ) , ionizing_radiation ( 31 ) , ionomycin ( 49 , 88 ) , KP-392 ( 78 ) , LLnL ( 47 , 72 , 90 ) , LPA ( 6 , 50 ) , LPS ( 8 , 66 , 73 , 78 ) , MG132 ( 34 , 51 , 55 , 64 , 74 ) , NAC ( 71 ) , NGF ( 85 ) , nocodazole ( 42 ) , okadaic_acid ( 104 ) , ONOO(-) ( 79 ) , parthenolide ( 64 ) , PD98059 ( 73 ) , PEITC ( 59 ) , phorbol_ester ( 49 , 88 , 92 , 93 , 101 , 104 ) , piceatannol ( 70 ) , poly(I-C) ( 91 ) , pomegranate_wine ( 71 ) , SB203580 ( 73 ) , seliciclib ( 45 ) , siRNA ( 44 , 50 , 55 ) , staurosporine ( 62 ) , sulforaphane ( 59 ) , taxol ( 80 ) , testosterone ( 62 ) , thrombin ( 54 , 60 ) , TNF ( 2 , 5 , 6 , 24 , 26 , 29 , 33 , 45 , 46 , 47 , 53 , 56 , 57 , 58 , 65 , 67 , 69 , 70 , 71 , 72 , 74 , 77 , 83 , 84 , 85 , 90 , 92 , 93 , 101 , 104 ) , TRAIL ( 5 ) , U0126 ( 57 ) , UV ( 35 , 59 , 69 , 74 ) , vanadate ( 34 , 53 , 69 , 90 ) , virus infection ( 26 , 35 , 44 ) , Z-VAD-FMK ( 5 )

Downstream Regulation
Effects of modification on IkB-alpha:
activity, induced ( 74 , 81 , 82 , 88 ) , intracellular localization ( 3 , 68 ) , molecular association, regulation ( 1 ) , phosphorylation ( 67 ) , protein degradation ( 3 , 33 , 55 , 57 , 58 , 60 , 63 , 65 , 74 , 75 , 78 , 80 , 84 , 88 , 91 , 92 , 99 , 101 , 104 , 105 , 106 )
Effects of modification on biological processes:
apoptosis, altered ( 58 , 81 ) , apoptosis, induced ( 80 ) , apoptosis, inhibited ( 33 , 69 , 82 ) , transcription, altered ( 33 , 65 , 67 , 76 , 81 , 82 , 88 ) , transcription, induced ( 55 , 69 , 104 , 105 )
Induce interaction with:
AurC (human) ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
HNSCC ( 28 )

References 

1

Han EH, et al. (2017) A small-molecule inhibitor targeting the AURKC-IκBα interaction decreases transformed growth of MDA-MB-231 breast cancer cells. Oncotarget 8, 69691-69708
29050234   Curated Info

2

Zimmermann S, et al. (2017) ALPK1- and TIFA-Dependent Innate Immune Response Triggered by the Helicobacter pylori Type IV Secretion System. Cell Rep 20, 2384-2395
28877472   Curated Info

3

Wu DD, et al. (2017) Extracellular signal-regulated kinase 8-mediated NF-κB activation increases sensitivity of human lung cancer cells to arsenic trioxide. Oncotarget 8, 49144-49155
28467781   Curated Info

4

Park JW, Zhao L, Willingham MC, Cheng SY (2017) Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor β. Mol Carcinog 56, 489-498
27254276   Curated Info

5

Sosna J, et al. (2016) Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells. Mol Cell Biol 36, 2626-44
27528614   Curated Info

6

Wakita M, et al. (2016) Phospholipase Cϵ Activates Nuclear Factor-κB Signaling by Causing Cytoplasmic Localization of Ribosomal S6 Kinase and Facilitating Its Phosphorylation of Inhibitor κB in Colon Epithelial Cells. J Biol Chem 291, 12586-600
27053111   Curated Info

7

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

8

De S, et al. (2015) Erlotinib protects against LPS-induced Endotoxicity because TLR4 needs EGFR to signal. Proc Natl Acad Sci U S A 112, 9680-5
26195767   Curated Info

9

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

10

Rikova K (2011) CST Curation Set: 13113; Year: 2011; Biosample/Treatment: cell line, MGH-1/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

11

Rikova K (2011) CST Curation Set: 13114; Year: 2011; Biosample/Treatment: cell line, MGH-2/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

12

Rikova K (2011) CST Curation Set: 13115; Year: 2011; Biosample/Treatment: cell line, MGH-3/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

13

Rikova K (2011) CST Curation Set: 13116; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

14

Rikova K (2011) CST Curation Set: 13117; Year: 2011; Biosample/Treatment: cell line, MGH-5/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

15

Rikova K (2011) CST Curation Set: 13118; Year: 2011; Biosample/Treatment: cell line, MGH-6/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

16

Rikova K (2011) CST Curation Set: 13119; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

17

Rikova K (2011) CST Curation Set: 13121; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

18

Rikova K (2011) CST Curation Set: 13122; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

19

Mulhern D (2011) CST Curation Set: 12704; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: DpSG
Curated Info

20

Dai Y, et al. (2011) Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. J Biol Chem 286, 34036-50
21816815   Curated Info

21

Malik SA, et al. (2011) BH3 mimetics activate multiple pro-autophagic pathways. Oncogene 30, 3918-29
21460857   Curated Info

22

Bhattacharyya S, et al. (2011) Specific effects of BCL10 Serine mutations on phosphorylations in canonical and noncanonical pathways of NF-{kappa}B activation following carrageenan. Am J Physiol Gastrointest Liver Physiol 301, G475-86
21700900   Curated Info

23

Kwiatkowska A, et al. (2011) Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta 1813, 655-67
21276823   Curated Info

24

Waiwut P, et al. (2011) Gomisin N enhances TNF-α-induced apoptosis via inhibition of the NF-κB and EGFR survival pathways. Mol Cell Biochem 350, 169-75
21188622   Curated Info

25

Guitton C, et al. (2011) Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-κB, and ERK1/2 MAP kinases. Am J Physiol Cell Physiol 300, C833-42
21228323   Curated Info

26

Diel DG, et al. (2011) Orf virus ORFV121 encodes a novel inhibitor of NF-kappaB that contributes to virus virulence. J Virol 85, 2037-49
21177808   Curated Info

27

Guo A (2011) CST Curation Set: 11300; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

28

Frederick MJ, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178, 548-71
21281788   Curated Info

29

Ju J, et al. (2010) Phosphorylation of p50 NF-kappaB at a single serine residue by DNA-dependent protein kinase is critical for VCAM-1 expression upon TNF treatment. J Biol Chem 285, 41152-60
20966071   Curated Info

30

Culver C, et al. (2010) Mechanism of Hypoxia-Induced NF-{kappa}B. Mol Cell Biol 30, 4901-21
20696840   Curated Info

31

Hinz M, et al. (2010) A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κB activation. Mol Cell 40, 63-74
20932475   Curated Info

32

Moritz A (2010) CST Curation Set: 10594; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

33

Peng C, et al. (2010) RSK2 mediates NF-{kappa}B activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway. FASEB J 24, 3490-9
20385620   Curated Info

34

Barisic S, Schmidt C, Walczak H, Kulms D (2010) Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFkappaB activation via Src-dependent blockade of PP2A. Biochem Pharmacol 80, 439-47
20450893   Curated Info

35

Yoboua F, et al. (2010) Respiratory syncytial virus-mediated NF-{kappa}B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK{beta}. J Virol 84, 7267-77
20410276   Curated Info

36

Wang H, Moreau F, Hirota CL, MacNaughton WK (2010) Proteinase-activated receptors induce interleukin-8 expression by intestinal epithelial cells through ERK/RSK90 activation and histone acetylation. FASEB J 24, 1971-80
20065107   Curated Info

37

Rikova K (2010) CST Curation Set: 9756; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

38

Rikova K (2010) CST Curation Set: 9764; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

39

Rikova K (2010) CST Curation Set: 9757; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

40

Rikova K (2010) CST Curation Set: 9767; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

41

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

42

Higashimoto T, Chan N, Lee YK, Zandi E (2008) Regulation of I(kappa)B kinase complex by phosphorylation of (gamma)-binding domain of I(kappa)B kinase (beta) by Polo-like kinase 1. J Biol Chem 283, 35354-67
18957422   Curated Info

43

Ho TC, et al. (2008) 15-deoxy-Delta(12,14)-prostaglandin J2 induces vascular endothelial cell apoptosis through the sequential activation of MAPKS and p53. J Biol Chem 283, 30273-88
18718914   Curated Info

44

Fink K, et al. (2008) Dual role of NOX2 in respiratory syncytial virus- and sendai virus-induced activation of NF-kappaB in airway epithelial cells. J Immunol 180, 6911-22
18453612   Curated Info

45

Dey A, et al. (2008) R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 15, 263-73
17975552   Curated Info

46

Seldon MP, et al. (2007) Heme oxygenase-1 inhibits the expression of adhesion molecules associated with endothelial cell activation via inhibition of NF-kappaB RelA phosphorylation at serine 276. J Immunol 179, 7840-51
18025230   Curated Info

47

Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB (2007) Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 26, 7324-32
17533369   Curated Info

48

Horion J, et al. (2007) Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappaB activation by delaying IkappaBalpha mRNA resynthesis: comparison with tumor necrosis factor alpha. J Biol Chem 282, 15383-93
17409387   Curated Info

49

Rueda D, et al. (2007) Bcl10 controls TCR- and FcgammaR-induced actin polymerization. J Immunol 178, 4373-84
17371994   Curated Info

50

Chiu TT, et al. (2007) Protein kinase D2 mediates lysophosphatidic acid-induced interleukin 8 production in nontransformed human colonic epithelial cells through NF-kappaB. Am J Physiol Cell Physiol 292, C767-77
16928771   Curated Info

51

Blonska M, et al. (2007) The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity 26, 55-66
17189706   Curated Info

52

Kammanadiminti SJ, Chadee K (2006) Suppression of NF-kappaB activation by Entamoeba histolytica in intestinal epithelial cells is mediated by heat shock protein 27. J Biol Chem 281, 26112-20
16840786   Curated Info

53

Gloire G, et al. (2006) Restoration of SHIP-1 activity in human leukemic cells modifies NF-kappaB activation pathway and cellular survival upon oxidative stress. Oncogene 25, 5485-94
16619039   Curated Info

54

Lin CH, et al. (2006) c-Src mediates thrombin-induced NF-kappaB activation and IL-8/CXCL8 expression in lung epithelial cells. J Immunol 177, 3427-38
16920985   Curated Info

55

Dolcet X, et al. (2006) Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 281, 22118-30
16735506   Curated Info

56

Song YJ, et al. (2006) IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation. Proc Natl Acad Sci U S A 103, 2689-94
16477006   Curated Info

57

Hu J, Haseebuddin M, Young M, Colburn NH (2005) Suppression of p65 phosphorylation coincides with inhibition of IkappaBalpha polyubiquitination and degradation. Mol Carcinog 44, 274-84
16163708   Curated Info

58

Kasperczyk H, et al. (2005) Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene 24, 6945-56
16007147   Curated Info

59

Xu C, et al. (2005) Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene 24, 4486-95
15856023   Curated Info

60

Minhajuddin M, et al. (2005) Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells. J Immunol 174, 5823-9
15843586   Curated Info

61

Zhang L, Cui R, Cheng X, Du J (2005) Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase. Cancer Res 65, 457-64
15695387   Curated Info

62

Cutolo M, et al. (2005) Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line. Arthritis Res Ther 7, R1124-32
16207329   Curated Info

63

Chen BC, et al. (2004) Bradykinin B2 receptor mediates NF-kappaB activation and cyclooxygenase-2 expression via the Ras/Raf-1/ERK pathway in human airway epithelial cells. J Immunol 173, 5219-28
15470067   Curated Info

64

Mattioli I, et al. (2004) Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappa B kinase beta and controls the kinetics of p65 nuclear import. J Immunol 172, 6336-44
15128824   Curated Info

65

Courtois G, et al. (2003) A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 112, 1108-15
14523047   Curated Info

66

Yang F, Tang E, Guan K, Wang CY (2003) IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 170, 5630-5
12759443   Curated Info

67

Jiang X, et al. (2003) The NF-kappa B activation in lymphotoxin beta receptor signaling depends on the phosphorylation of p65 at serine 536. J Biol Chem 278, 919-26
12419817   Curated Info

68

Nair A, et al. (2003) NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22, 50-8
12527907   Curated Info

69

Fan C, Yang J, Engelhardt JF (2002) Temporal pattern of NFkappaB activation influences apoptotic cell fate in a stimuli-dependent fashion. J Cell Sci 115, 4843-53
12432072   Curated Info

70

Ashikawa K, et al. (2002) Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol 169, 6490-7
12444159   Curated Info

71

Schubert SY, Neeman I, Resnick N (2002) A novel mechanism for the inhibition of NF-kappaB activation in vascular endothelial cells by natural antioxidants. FASEB J 16, 1931-3
12368228   Curated Info

72

Mukhopadhyay A, et al. (2002) Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors. J Biol Chem 277, 30622-8
12060665   Curated Info

73

Mancuso G, et al. (2002) Mitogen-activated protein kinases and NF-kappa B are involved in TNF-alpha responses to group B streptococci. J Immunol 169, 1401-9
12133965   Curated Info

74

Huang TT, Feinberg SL, Suryanarayanan S, Miyamoto S (2002) The zinc finger domain of NEMO is selectively required for NF-kappa B activation by UV radiation and topoisomerase inhibitors. Mol Cell Biol 22, 5813-25
12138192   Curated Info

75

Kim BY, et al. (2002) Constitutive activation of NF-kappaB in Ki-ras-transformed prostate epithelial cells. Oncogene 21, 4490-7
12085227   Curated Info

76

Kim MO, et al. (2002) Interferon-beta activates multiple signaling cascades in primary human microglia. J Neurochem 81, 1361-71
12068083   Curated Info

77

Bhat-Nakshatri P, Sweeney CJ, Nakshatri H (2002) Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene 21, 2066-78
11960379   Curated Info

78

Tan C, Mui A, Dedhar S (2002) Integrin-linked kinase regulates inducible nitric oxide synthase and cyclooxygenase-2 expression in an NF-kappa B-dependent manner. J Biol Chem 277, 3109-16
11724787   Curated Info

79

Matata BM, Galiñanes M (2002) Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. J Biol Chem 277, 2330-5
11706022   Curated Info

80

Huang Y, Fan W (2002) IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol 61, 105-13
11752211   Curated Info

81

Kasof GM, et al. (2001) Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene 20, 7965-75
11753679   Curated Info

82

Brandes LM, Lin ZP, Patierno SR, Kennedy KA (2001) Reversal of physiological stress-induced resistance to topoisomerase II inhibitors using an inducible phosphorylation site-deficient mutant of I kappa B alpha. Mol Pharmacol 60, 559-67
11502888   Curated Info

83

Salmerón A, et al. (2001) Direct phosphorylation of NF-kappaB1 p105 by the IkappaB kinase complex on serine 927 is essential for signal-induced p105 proteolysis. J Biol Chem 276, 22215-22
11297557   Curated Info

84

Place RF, Haspeslagh D, Hubbard AK, Giardina C (2001) Cytokine-induced stabilization of newly synthesized I(kappa)B-alpha. Biochem Biophys Res Commun 283, 813-20
11350057   Curated Info

85

Bui NT, Livolsi A, Peyron JF, Prehn JH (2001) Activation of nuclear factor kappaB and Bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IkappaBalpha. J Cell Biol 152, 753-64
11266466   Curated Info

86

Deng L, et al. (2000) Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-61
11057907   Curated Info

87

Huynh QK, et al. (2000) Characterization of the recombinant IKK1/IKK2 heterodimer. Mechanisms regulating kinase activity. J Biol Chem 275, 25883-91
10823818   Curated Info

88

Schoonbroodt S, et al. (2000) Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. J Immunol 164, 4292-300
10754328   Curated Info

89

Bren GD, Pennington KN, Paya CV (2000) PKC-zeta-associated CK2 participates in the turnover of free IkappaBalpha. J Mol Biol 297, 1245-58
10764587   Curated Info

90

Mukhopadhyay A, Manna SK, Aggarwal BB (2000) Pervanadate-induced nuclear factor-kappaB activation requires tyrosine phosphorylation and degradation of IkappaBalpha. Comparison with tumor necrosis factor-alpha. J Biol Chem 275, 8549-55
10722693   Curated Info

91

Gil J, Alcamí J, Esteban M (2000) Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex. Oncogene 19, 1369-78
10723127   Curated Info

92

Peters RT, Liao SM, Maniatis T (2000) IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell 5, 513-22
10882136   Curated Info

93

Taylor JA, et al. (1999) Serine 32 and serine 36 of IkappaBalpha are directly phosphorylated by protein kinase CKII in vitro. J Mol Biol 290, 839-50
10398585   Curated Info

94

Winston JT, et al. (1999) The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 13, 270-83
9990852   Curated Info

95

Heilker R, et al. (1999) All three IkappaB isoforms and most Rel family members are stably associated with the IkappaB kinase 1/2 complex. Eur J Biochem 259, 253-61
9914500   Curated Info

96

Sylla BS, et al. (1998) Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci U S A 95, 10106-11
9707608   Curated Info

97

Desterro JM, Rodriguez MS, Hay RT (1998) SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 2, 233-9
9734360   Curated Info

98

Mercurio F, et al. (1997) IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278, 860-6
9346484   Curated Info

99

DiDonato JA, et al. (1997) A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388, 548-54
9252186   Curated Info

100

Rodriguez MS, et al. (1996) Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo. Oncogene 12, 2425-35
8649784   Curated Info

101

DiDonato J, et al. (1996) Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 16, 1295-304
8657102   Curated Info

102

Baldi L, Brown K, Franzoso G, Siebenlist U (1996) Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. J Biol Chem 271, 376-9
8550590   Curated Info

103

Scherer DC, et al. (1995) Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A 92, 11259-63
7479976   Curated Info

104

Traenckner EB, et al. (1995) Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 14, 2876-83
7796813   Curated Info

105

Brockman JA, et al. (1995) Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol 15, 2809-18
7739562   Curated Info

106

Brown K, et al. (1995) Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267, 1485-8
7878466   Curated Info